Centre for Research and Development, Uppsala University/County Council of Gävleborg, S-80188 Gävle, Sweden.
BMJ. 2012 Mar 1;344:e900. doi: 10.1136/bmj.e900.
To determine whether detection of invasive cervical cancer by screening results in better prognosis or merely increases the lead time until death.
Nationwide population based cohort study.
Sweden.
All 1230 women with cervical cancer diagnosed during 1999-2001 in Sweden prospectively followed up for an average of 8.5 years.
Cure proportions and five year relative survival ratios, stratified by screening history, mode of detection, age, histopathological type, and FIGO (International Federation of Gynecology and Obstetrics) stage.
In the screening ages, the cure proportion for women with screen detected invasive cancer was 92% (95% confidence interval 75% to 98%) and for symptomatic women was 66% (62% to 70%), a statistically significant difference in cure of 26% (16% to 36%). Among symptomatic women, the cure proportion was significantly higher for those who had been screened according to recommendations (interval cancers) than among those overdue for screening: difference in cure 14% (95% confidence interval 6% to 23%). Cure proportions were similar for all histopathological types except small cell carcinomas and were closely related to FIGO stage. A significantly higher cure proportion for screen detected cancers remained after adjustment for stage at diagnosis (difference 15%, 7% to 22%).
Screening is associated with improved cure of cervical cancer. Confounding cannot be ruled out, but the effect was not attributable to lead time bias and was larger than what is reflected by down-staging. Evaluations of screening programmes should consider the assessment of cure proportions.
确定通过筛查检测出的宫颈癌是否能改善预后,还是仅仅增加了直至死亡的时间。
全国性基于人群的队列研究。
瑞典。
所有 1230 名于 1999 年至 2001 年期间在瑞典被诊断患有宫颈癌的女性,平均随访 8.5 年。
按筛查史、检出方式、年龄、组织病理学类型和国际妇产科联合会(FIGO)分期分层的治愈率和五年相对生存率。
在筛查年龄段,筛查发现的浸润性宫颈癌女性的治愈率为 92%(95%置信区间为 75%至 98%),而症状性女性为 66%(62%至 70%),治愈率相差 26%(16%至 36%),有统计学意义。在症状性女性中,根据建议进行筛查(间隔期癌症)的患者治愈率明显高于筛查延误的患者:治愈率相差 14%(95%置信区间为 6%至 23%)。除小细胞癌外,所有组织病理学类型的治愈率均相似,且与 FIGO 分期密切相关。在诊断时调整分期后,筛查发现的癌症仍有更高的治愈率(差异为 15%,7%至 22%)。
筛查与宫颈癌治愈率的提高有关。虽然不能排除混杂因素,但这种影响不是归因于领先时间偏倚,而且比分期降级所反映的影响更大。筛查项目的评估应考虑治愈率的评估。